Skip to main content
← Back to companies
BioEclipse Therapeutics logo

BioEclipse Therapeutics

0 open1 filled
San Francisco, California, United StatesFounded 20067+ employees$15.7M raisedSeries APrivate
Last round: grant · $8M · Apr 2022(4 rounds total)
Founded by Chris Contag, Pamela Contag, Robert Negrin
Backed by(6 investors)
California Institute for Regenerative MedicineRevelis Capital GroupDEFTA PartnersPlum AlleyFoothill VenturesTSVC

BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary technology to develop the next generation of immuno-oncology therapeutics. Foundationally, we have harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics™ pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. The result of this combination is a multi-mechanistic, targeted treatment that we believe will not only eradicate cancer cells, but also protect the patient from relapse and recurrence, through a durable immune response that prevents the development of new cancers, even in the face of new challenges from disease.

Open Positions at BioEclipse Therapeutics (0 Jobs)

No open positions at the moment.

Browse All Jobs

Ready to start your space career at BioEclipse Therapeutics?

Shipping like we're funded. We're not. No affiliation.

Sequoia logo
Y Combinator logo
Founders Fund logo
a16z logo